
ISSN 1920-4159 | J App Pharm
An international, peer-reviewed, open access journal of the pharmaceutical and allied health sciences, published online since 2009
ISSN 1920-4159 · Journal DOI 10.21065/19204159 · Abbreviation: J Appl Pharm · Published annually in English
The Journal of Applied Pharmacy publishes original research, reviews and scholarly communications in the pharmaceutical and allied health sciences. Its aim is to strengthen the evidence base for the safe, effective and affordable use of medicines.
Pharmacy is the science of discovering, developing, formulating, evaluating and dispensing medicines. Pharmacists help patients get the best results from drug therapy through pharmaceutical care, therapeutic drug monitoring and patient-centred practice. The journal links basic pharmaceutical research with clinical and professional practice. All articles are free to read, download and reuse from the day of publication.
Key title: Journal of Applied Pharmacy
Abbreviation: J Appl Pharm
ISSN (Online): 1920-4159
Crossref DOI: https://doi.org/10.21065/19204159
Zenodo DOI: https://doi.org/10.5281/zenodo.15098637
Editor-in-Chief: Dr. Taha Nazir
First published: 2009
Frequency: Annual (articles published online on acceptance)
Format: Online only
Language: English
Peer review: Editorial assessment, then double-blind review by at least two independent reviewers
Average time to first decision: 6 weeks
Licence: CC BY 4.0
Copyright: Journal, publisher and authors (jointly held)
Publication charges: No submission fee; APC CA$100 (after acceptance)
Waivers: Full or partial waivers for authors from low- and middle-income countries and on justified request
Plagiarism screening: All manuscripts are checked with text-matching software and AI-assisted tools
Publication ethics: Follows COPE guidelines and the ICMJE Recommendations
Archiving: Zenodo
Self-archiving: Authors may deposit any version in institutional or subject repositories without embargo
Persistent identifiers: DOI for every article; ORCID iDs requested for all authors
Metadata: Deposited with Crossref
Indexing: Crossref, Zenodo, Google Scholar and the NLM Catalog (NLM ID 101576162); see the Indexing page
Submission: Online
Publisher: Consortium Publisher – ICDTD Inc., Canada
Contact: office@consortiumpublisher.ca · +1 (647) 526-0885
The journal publishes original work on the discovery, development, analysis, production and use of medicines, and on their therapeutic outcomes. Natural products and semi-synthetic derivatives are welcome. The journal values research that links a clear pharmaceutical question to sound methods and validated analysis, with conclusions that stay within the evidence. Acceptance depends mainly on scientific rigour and the potential to advance the field.
The journal aims to:
Publish reproducible research across the pharmaceutical and allied health sciences.
Connect laboratory and industrial pharmaceutical research with clinical, hospital and community practice.
Support the safe, effective and affordable use of medicines through evidence that informs practice, regulation and policy.
Make every article openly available, so that researchers, pharmacists, clinicians, regulators, educators and students everywhere can use it without cost.
Within scope: laboratory, industrial, clinical and practice-based studies that use appropriate controls, validated analytical methods and sound statistical analysis. Systematic reviews and evidence-based policy reviews are also within scope.
Outside scope: promotional studies of commercial products, unsupported therapeutic claims, and reports of natural products with no identification or standardisation of the material. Studies whose conclusions rest on data that are not made available for review are also outside scope.
The subject areas are grouped into seven themes. They run from how a medicine is made and measured, through how it acts in the body, to how it reaches and helps patients.
1. Pharmaceutics and drug delivery. Pharmaceutics, physical pharmacy, dosage form science, biopharmaceutics, pharmaceutical technology and industrial pharmacy. This theme asks how medicines are formulated, manufactured and delivered so that they work reliably in the body.
2. Pharmaceutical and medicinal chemistry and analysis. Pharmaceutical chemistry, medicinal chemistry, biochemistry, and pharmaceutical analysis and instrumentation. This theme asks how drug molecules are designed, made, characterised and measured.
3. Pharmacognosy and natural products. Pharmacognosy, medicinal plants, and natural products and their semi-synthetic derivatives. This theme asks which medicines can be found in plants, microbes and other natural sources, and how they can be standardised.
4. Pharmacology, therapeutics and biomedical sciences. Pharmacology and therapeutics, pharmaceutical microbiology and immunology, physiology, histology, anatomy and pathology. This theme asks how drugs act on the body and on disease, and how safe and effective they are.
5. Clinical, hospital and community pharmacy practice. Clinical pharmacy, hospital pharmacy, community pharmacy, pharmacy practice, dispensing, pharmaceutical care and therapeutic drug monitoring. This theme asks how pharmacists can improve the results of drug therapy for patients.
6. Social and administrative pharmacy and regulation. Social and administrative pharmacy, pharmaceutical management and marketing, drug regulation and governance, pricing and access to medicines, and forensic pharmacy. This theme asks how law, regulation, economics and management shape access to safe and affordable medicines.
7. Quality management and biostatistics. Pharmaceutical quality management, pharmaceutical mathematics and biostatistics. This theme asks how the quality of medicines can be assured, and how pharmaceutical data can be analysed soundly.
Work from universities, hospitals, industry, regulatory agencies and community practice is welcome in every theme.
Original research article: reports new laboratory, industrial, clinical or practice-based findings that answer a defined research question.
Review article: critically synthesises published evidence on a topic and identifies open questions. Systematic reviews should follow PRISMA.
Case report: describes a patient or case, such as an adverse drug reaction or unusual treatment response, that adds new knowledge. Case reports should follow the CARE guidelines.
Methods and techniques: describes a new or substantially improved analytical, formulation or manufacturing method, with validation data.
Short communication: reports a focused, significant finding that does not need a full article.
Commentary or perspective: offers an evidence-based viewpoint on a current issue in pharmacy or pharmaceutical policy.
Letter to the editor: responds briefly to an article published in the journal.
All article types are peer reviewed except editorials, letters and corrections.
The Journal of Applied Pharmacy is a fully open access journal that follows the Directory of Open Access Journals (DOAJ) definition of open access. All articles are free to read immediately on publication, with no subscription, registration or embargo.
Licence. Articles are published under the Creative Commons Attribution 4.0 International licence (CC BY 4.0). Anyone may read, download, copy, distribute, print, search or link to the full text, crawl it for indexing, pass it as data to software, or use it for any other lawful purpose, as long as the original authors and source are properly cited. The licence statement appears on every article page and in the article PDF.
Copyright. The journal, the publisher (Consortium Publisher – ICDTD Inc.) and the authors hold copyright of each article jointly. The journal has the right to publish the article first. Because articles are published under CC BY 4.0, anyone may reuse them with proper citation. Authors may deposit any version of their article, including the published version, in institutional or subject repositories at any time, without embargo.
Third-party material. Authors must get permission for any figures, chemical structures, tables or text reused from other sources and label them with their original licence.
There is no charge to read any article, and there is no submission fee.
Article processing charge (APC): CA$100. It is charged only after a manuscript is accepted, never for submission or review. The APC applies to manuscripts submitted from 1 July 2026. Manuscripts submitted up to 30 June 2026 are exempt.
The APC never influences editorial decisions. Full or partial waivers are available on request for authors from low- and middle-income countries and for authors without funding.
Every submission first receives an editorial assessment of its scope, originality and research integrity, including a similarity check. Manuscripts that pass are assessed by at least two independent expert reviewers under a double-blind model. Reviewers do not know the authors’ identities, and authors do not know the reviewers’. The average time from submission to first decision is six weeks. Decisions rest on scientific validity, methodological soundness, ethical compliance and contribution to the field, not on the expected impact or citation of the work.
Editorial independence. An editor with a conflict of interest in a manuscript does not handle it. This includes manuscripts from the editor’s own institution and the editor’s own submissions, including those of the Editor-in-Chief. Such manuscripts are assigned to another editor and reviewed under the same process. The publisher does not take part in editorial decisions.
The journal follows the Core Practices of the Committee on Publication Ethics (COPE) and the ICMJE Recommendations for the conduct, reporting and editing of scholarly work.
Originality and plagiarism. Every submission is screened with text-matching software and AI-assisted tools before review. Plagiarism, duplicate publication and redundant publication lead to rejection or, after publication, retraction.
Data and image integrity. Data, chromatograms, spectra, blots and micrographs must not be fabricated, selectively reported or altered in ways that misrepresent the findings. Editors may request raw data or original images.
Human research. Studies involving people, patient data or human samples must have approval from a named ethics committee and record informed consent. They must follow the Declaration of Helsinki and Canada’s TCPS 2.
Case reports. The patient’s written consent to publication is required.
Clinical trials and reporting standards. Clinical trials must be registered in a public registry before enrolment begins and reported according to CONSORT. Observational studies should follow STROBE.
Animal research. Studies involving animals must have institutional approval, follow the Canadian Council on Animal Care (CCAC) guidelines or an equivalent, and be reported according to ARRIVE.
Analytical methods. Analytical methods should be validated according to the ICH Q2 guideline or an equivalent standard.
Natural products. Plant and other natural materials must be authenticated, and voucher specimens deposited in a recognised herbarium or collection, with their numbers given.
Authorship. All authors must meet the ICMJE authorship criteria. Authors are encouraged to describe each contribution using the CRediT taxonomy and to provide an ORCID iD.
Conflicts of interest and funding. Authors must disclose all funding and any financial or professional interest that could affect the work. This includes funding from, employment by, or consulting for pharmaceutical, medical device or supplement companies.
Data availability. Each article includes a data availability statement. Where possible, data should be shared in a public repository. Where they cannot be shared, the statement explains why and how they can be accessed.
Use of artificial intelligence. AI tools cannot be listed as authors. Any use of AI in research or writing must be disclosed in the Methods or Acknowledgements, and authors remain responsible for all content.
Corrections and retractions. Errors are corrected through linked correction notices. Retractions follow COPE guidelines and remain openly accessible, with the reason stated.
Complaints and appeals. Authors may appeal a decision by writing to the editorial office with their reasons. Concerns about published work are handled according to the COPE flowcharts.
Every article receives a permanent Digital Object Identifier (DOI) registered with Crossref under the journal DOI 10.21065/19204159. The DOI means an article can always be found and cited, even if web addresses change. Published content is also deposited in Zenodo (https://doi.org/10.5281/zenodo.15098637). ORCID iDs are requested for all authors.
Machine-readable metadata. Article metadata is deposited with Crossref, so indexing services and software can harvest it. The metadata includes titles, authors, affiliations, abstracts, references, licence and funding.
Manuscripts are submitted and processed online, and authors can follow each stage of review in their account. The journal is published by Consortium Publisher – ICDTD Inc., Canada. Its website is hosted on Bravo Journal Systems (BJS) of Bravo Skills College, Port of Spain, Trinidad and Tobago.
Before submitting, please read the Author Guidelines and prepare a cover letter. Include statements on ethics approval, consent, trial registration where relevant, funding, conflicts of interest and data availability.
[Submit a manuscript] · [Author Guidelines] · [Editorial Board] · [Contact the editorial office]
Some third parties have contacted researchers and asked for manuscripts in the name of the Journal of Applied Pharmacy without permission. Consortium Publisher – ICDTD Inc. has not authorized these groups and is not affiliated with them. It accepts no responsibility for any submission, payment, communication or statement made through them.
Deceptive practices like these have led to regulatory action. In 2016, the U.S. Federal Trade Commission (FTC) charged a group of publishers with deceiving researchers. A U.S. federal court in Las Vegas, Nevada, later granted summary judgment in the FTC’s favour. Authors should submit manuscripts only through the journal’s official website and should check any unexpected request with the editorial office.